Neuwave Medical roped in $25 million in equity funding to support development of its soft tissue ablation system, ramping up operations as it expands the reach for its innovative surgical system.
A heavyweight consortium of Chinese biomedical- and healthcare-focused funds said it would acquire San Diego-based biotech Ambrx, which abandoned an initial public offering last year, in a deal that opens a path to cutting-edge candidates in oncology therapies.
Australia has singled out the pharmaceutical industry for special scrutiny in its examination of corporations moving money offshore to avoid local taxes.
Outside of surgery, physicians can do very little to treat severe rotator cuff tears. Israeli company OrthoSpace is aiming to offer a new treatment option. It's raised an $8 million venture round led by Healthpoint Capital that will finance a pivotal, U.S. trial for the company's biodegradable balloon system InSpace.
San Francisco startup Metabiota raked in $30 million in Series A funding to ramp up operations as it looks to increase its market reach for its disease outbreak prediction tools.
China's Sinocare reportedly has made a $1 billion bid for Germany-based Bayer's diabetes devices. As maker of blood-sugar monitors, Sinocare would be challenging a broader based company, Panasonic Healthcare, already months into discussions with the seller.
Outset Medical got its Tablo all-in-one diabetes dialysis device cleared by FDA in November. Now investors, including existing backers Warburg Pincus and The Vertical Group, are ponying up $59.6 million to back marketing the device to dialysis clinics as well as to complete a pivotal trial for home use.
Eli Lilly has led a Series B round for San Diego, CA-based startup Companion Medical. The financing is expected to enable the completion of testing and 510(k) submission for its Bluetooth-enabled insulin pen and accompanying smartphone app. The amount of the financing was undisclosed.
A year removed from taking a private equity buyout, U.K. CRO Quotient Clinical has watched demand for its services spike, the company said, plotting some major investments to keep the pace of growth.
India regulators have cleared Glenmark Pharmaceuticals to sell as much as 49% of its shares to foreign institutional investors, up from its former 40% limit, and paving the way for major investors such as Singapore's Temasek Holdings.